Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Short Communication
Authors: Oeckl, Patricka | Halbgebauer, Steffena | Anderl-Straub, Saraha | Steinacker, Petraa | Huss, André M.a | Neugebauer, Hermanna | von Arnim, Christine A.F.a | Diehl-Schmid, Janineb | Grimmer, Timob | Kornhuber, Johannesc | Lewczuk, Piotrc; d | Danek, Adriane | Consortium for Frontotemporal Lobar Degeneration Germanf | Ludolph, Albert C.a | Otto, Markusa; *
Affiliations: [a] Department of Neurology, Ulm University Hospital, Ulm, Germany | [b] Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technical University of Munich, München, Germany | [c] Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen and Friedrich-Alexander-University of Erlangen Nuremberg, Erlangen, Germany | [d] Department of Neurodegeneration Diagnostics, Medical University of Bialystok, Bialystok, Poland | [e] Department of Neurology, University Hospital, LMU Munich, München, Germany | [f] German Consortium for Frontotemporal Lobar Degeneration, University of Ulm, Ulm, Germany (http://www.ftld.de)
Correspondence: [*] Correspondence to: Prof. Dr. med. Markus Otto, Department of Neurology, Ulm University Hospital, Oberer Eselsberg 45, D-89081 Ulm, Germany. Tel.: +49 731 500 63010; Fax.: +49 731 500 63012; E-mail: markus.otto@uni-ulm.de.
Abstract: Reliable blood biomarkers for Alzheimer’s disease (AD) are missing. We measured astroglial GFAP in patients with AD (n = 28), frontotemporal dementia (bvFTD, n = 35), Parkinson’s disease (n = 11), Lewy body dementias (n = 19), and controls (n = 34). Serum GFAP was increased in AD (p < 0.001) and DLB/PDD (p < 0.01), and cerebrospinal fluid GFAP was increased in all neurodegenerative diseases (p < 0.001). Serum GFAP correlated with the Mini-Mental State Examination score (r= –0.42, p < 0.001) and might be a follow-up marker in clinical trials. Sensitivity and specificity of serum GFAP for AD versus bvFTD was 89% and 79% and might be the first blood biomarker in the differential diagnosis of AD and bvFTD.
Keywords: Alzheimer’s disease, astrocyte, biomarker, cerebrospinal fluid, differential diagnosis, frontotemporal dementia, GFAP, Lewy body dementia, Parkinson’s disease, serum
DOI: 10.3233/JAD-180325
Journal: Journal of Alzheimer's Disease, vol. 67, no. 2, pp. 481-488, 2019
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl